Research peptides, documented.
78 research compounds in multi-vial kits. Every product page sets out the mechanism of action and the published studies behind it, linked to PubMed.
78 products
across 10 research areas
Studies linked to PubMed
on every compound page
Single kits or bulk
volume quantities on request
Research use only
buyers must be 21 or older
Shop by research area
The catalog is organized by the biological system each compound is studied in.
- METMetabolic & Incretin12Tirzepatide · Retatrutide · Semaglutide · Cagrilintide · Cagrilintide 5mg + Semaglutide 5mg
- GHGrowth Hormone & IGF14CJC-1295 Without DAC · CJC-1295 With DAC · CJC-1295 Without DAC 5mg + IPA 5mg · Ipamorelin · Sermorelin
- RECRecovery & Repair5BPC-157 · TB-500 · BPC-157 + TB-500 · BPC-157 + GHK-Cu + TB-500 · KLOW
- COGCognitive & Sleep10Semax · Selank · NA Selank Amidate · Semax + Selank · Pinealon
- LONLongevity & Mitochondrial9Epithalon · SS-31 · MOTS-c · NAD+ · FOXO4
- IMMImmune & Inflammation6Thymosin Alpha-1 · Thymalin · LL-37 · KPV · VIP
- HORHormonal & Melanocortin7PT-141 · MT-1 · MT-2 · KissPeptin-10 · Oxytocin Acetate
- SKNSkin & Cosmetic4GHK-Cu · AHK-Cu · Snap-8 · Lemon Bottle
- LIPLipotropic & Vitamin10Lipo-C Fat Blaster · Lipo-C with B12 · Lipo-C · Super Shred · Lipo-C Focus
- SUPLab Supplies1Bac Water
Featured compounds
- MetabolicTR5
Tirzepatide
Tirzepatide is a synthetic peptide that activates both the GIP and GLP-1 receptors. Researchers study it to understand how combined incretin receptor signaling affects glucose control, body weight, and related metabolic outcomes.
10 sizes · 5mg–100mg - MetabolicRT5
Retatrutide
Retatrutide is an investigational single peptide that activates the GIP, GLP-1, and glucagon receptors. Researchers study it to test whether adding glucagon receptor activity to incretin agonism increases weight reduction and metabolic effects.
8 sizes · 5mg–60mg - MetabolicSM2
Semaglutide
Semaglutide is a long-acting analogue of human GLP-1. It is one of the most extensively studied incretin-based compounds, with large trials in type 2 diabetes, obesity, and cardiovascular outcomes.
6 sizes · 2mg–30mg - GH & IGFCND2
CJC-1295 Without DAC
A modified 29-amino-acid fragment of growth hormone-releasing hormone, engineered to resist the rapid enzymatic breakdown that limits the native peptide.
3 sizes · 2mg–10mg - GH & IGFIP5
Ipamorelin
A synthetic pentapeptide that stimulates growth hormone release through the ghrelin receptor, noted in early work for its selectivity.
2 sizes · 5mg–10mg - RecoveryBC5
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. It is studied mainly in rodent models of tendon, muscle, gastrointestinal and vascular injury.
4 sizes · 5mg–20mg - RecoveryBT5
TB-500 (Thymosin B4 Acetate)
TB-500 is a trade name for synthetic thymosin beta-4, a 43-amino-acid peptide that binds monomeric actin. Researchers study thymosin beta-4 for roles in cell migration, wound repair, angiogenesis, and cardiac and corneal injury.
2 sizes · 5mg–10mg - CognitiveXA5
Semax
A synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH). Researchers study it for reported effects on brain neurotrophin expression, learning in rodents, and outcomes in models of cerebral ischemia.
2 sizes · 5mg–10mg
Every product page is a research brief.
What the compound is, how it acts, what the published studies found, and where the evidence stops. Each study links to its PubMed record, and every size is listed exactly as catalogued.
Read the Tirzepatide page- Activates the GIP receptor with potency similar to native GIP and the GLP-1 receptor with lower potency than native GLP-1, an imbalanced profile that favors GIP receptor signaling.
- At the GLP-1 receptor it favors cAMP signaling over beta-arrestin recruitment, a bias that cell studies link to reduced receptor internalization.
- Both receptor actions increase glucose-dependent insulin secretion from pancreatic beta cells. Clinical studies have also reported lower glucagon levels and improved insulin sensitivity.
2022
PMID 35658024Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, et al. · N Engl J Med
SURMOUNT-1 randomized 2,539 adults with obesity without diabetes for 72 weeks. Mean body-weight reductions were 15.0% to 20.9% across three dose levels versus 3.1% with placebo.
| Catalog no. | Specification |
|---|---|
| TR5 | 5mg *10vials |
| TR10 | 10mg *10vials |
| TR15 | 15mg *10vials |
| TR20 | 20mg *10vials |
| + 6 more sizes | |
Ordering for a lab or a resale catalog?
Tell us the compounds, sizes and kit quantities you need. We reply with volume pricing and availability.